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The use of highly active antiretroviral therapy (HAART) has extended the lifespan of
patients infected with human immunodeﬁciency virus (HIV). As the prognosis of HIV
infection has improved, liver disease associated with hepatitis C virus (HCV) has become
clinically signiﬁcant in patients with HIV, liver failure being a frequent cause of death in
this population. HIV infection may accelerate the course of liver disease in patients co-
infected with HCV, so infection with HCV should be treated like any other opportunistic
disease in these patients. Nowadays, combination therapy with interferon-alpha and
ribavirin is the standard treatment for chronic hepatitis C in HIV-negative patients.
Preliminary results of combination therapy in HIV/HCV co-infected patients have been
promising, showing a sustained response rate in 40% of these patients. Patients with
higher CD4 counts and lower HCV/HIV viral load and those infected with HCV
genotype 3a have a better response to therapy. Potential drug interactions between
HAART therapy and interferon and ribavirin treatment emphasize the importance of
initiating treatment of HCV infection in HIV-positive individuals as soon as possible and
ideally before the need for anti-HIV therapy. Recent case reports have suggested that
liver transplantation might be an appropriate procedure in HIV patients with undetect-
able HIV viral load, high CD4 counts and HCV advanced liver disease. However, the
limited amount of available information and the complexities of drug interactions
between HAART therapy and immunosuppressive drugs oblige us to be prudent within
considering such a procedure.
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HIV and hepatitis C virus (HCV) co-infection is a
signiﬁcant clinical phenomenon. As many as 33%
of patients with HIV infection are also infected by
HCV, but this ﬁgure rises to 60–90% of injection
drug users and of persons with hemophilia [1].
Since 1996, the use of highly active antiretroviral
therapy (HAART) has extended the lifespan of
patients infected with human immunodeﬁciency
virus (HIV). As the prognosis for HIV infection has
improved, liver disease associated with HCV has
become clinically signiﬁcant in patients with HIV,
liver failure being a frequent cause of death in this
population [2].
Studies on the natural history of HCV infection
in immunocompetent persons have shown that 6%
of them will develop liver decompensation due to
cirrhosis during a 20-year period [3]. A number of
studies have suggested that HIV infection may
accelerate the course of liver disease in patients
co-infected with HCV [3,4], ﬁbrosis occurring at a
faster rate [5,6] and hepatic decompensation, liver-
related death and hepatocarcinoma developing
more often, than in non-HIV patients [7]. Benha-
mou et al. [6] have recently estimated the mean
time for developing liver cirrhosis in patients with
HIV/HCV co-infection as 26 years (range 22–34) in
comparison with 34 years (range 32–47), in non-
HIV-infected patients.
On the other hand, although it is less clear
whether HCV infection has an effect on the natural
history of HIV infection, it has been suggested [8]
that co-infection by HCV may affect it adversely.
HIV/HCV-co-infected patients are more likely to
have increasing HIV viral load and decreasing
CD4 counts comparedwith those not infected with
both viruses [9]. It is important to consider that the
risk of liver failure in HIV patients with hepatitis C
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is inversely correlatedwith CD4 cell counts [10,11],
so maintenance of CD4 lymphocyte levels must be
viewed as an absolute priority in these patients.
Thus, appropriate therapy for decreasing HIV
replication is an important strategy in the treat-
ment of HCV-related chronic liver disease in these
patients.
Because of the effect of HIV on the natural
history of HCV disease, infection with HCV
should be treated like any other opportunistic
disease, as has been stated by the US Public Health
Service and the Infectious Diseases Society of
America in their 1999 guidelines: ‘HIV–HCV coin-
fected patients have a higher incidence of chronic
liver disease than patients infected with HIV alone
and should be evaluated for chronic liver disease
and for the possible need for treatment’ [12]. The
goals for the treatment of HCV infection in HCV/
HIV-co-infected individuals are: (1) to prevent the
development of cirrhosis and its complications; (2)
to reduce the extrahepatic manifestations; and (3)
to prevent the contamination of other people.
Several studies have shown a beneﬁcial effect of
recombinant interferon-alpha (IFN-a) in HIV-posi-
tive patients with chronic hepatitis C [13–17]. The
response rate is not signiﬁcantly different from
that observed in HIV-non-infected patients
[16,18]. Alanine aminotransferase level normaliza-
tion at the end of treatment is achieved in 32–55%
of patients, and a sustained response occurred in
8–38% of patients with HIV/HCV after a 12-month
follow-up. A prospective trial, which included 119
patients with chronic hepatitis C, 90 of whomwere
infected with HIV and 29 of whom were not,
showed a complete response after 12months of
therapy in 32.5% of HIV-infected patients and in
37% of non-HIV-infected patients (P¼ 0,66), and
relapses occurred in 30.8% of the HIV-infected
patients and in 12.5% of non-HIV-infected patients
(P¼ 0.4) [16]. This study, in addition to others,
demonstrated a tendency toward better response
among HIV-co-infected patients who had a higher
CD4 count (>500 106/L) [15–17]. Lower HCV
viremia and genotype 3a were also found to be
predictors of response among these patients [19].
Histologic improvement 1 year after the end of
therapy was observed not only in responders
but also in non-responders and those who re-
lapsed [15,16,19]. In the majority of these studies,
the tolerance and side-effects of treatment were
found to be no different between the HCV/
HIV-co-infected patients and the HIV-uninfected
patients. The more frequent side-effects associated
with interferon therapy are ﬂu-like syndrome,
headache, fatigue, myalgia, anorexia and throm-
bocytopenia. Although interferon treatment was
usually generally well tolerated, in a recent pro-
spective study of 153 patients with chronic
hepatitis C, 76 of whom were co-infected with
HIV, four serious side-effects were reported, two
among HIV-negative patients and two among
HIV-positive patients: two patients (one from
each group) made unsuccessful suicide attempts,
an HIV-infected patient died during follow-up
11.9months after starting treatment from decom-
pensated cirrhosis with ascites and septicemia,
and one non-HIV-infected patient showed a
ﬂare-up of transaminases without known etiology
[18]. During IFN-a therapy, a decrease in the CD4
cell count may occur in about 5% of patients
[20,21], but this decline is transient and reversible,
and does not appear to increase the risk of oppor-
tunistic infection [22]. Although this decrease in
CD4 count is a rare event, it is mandatory to
control the CD4 cell count during IFN-a treatment
of HIV-infected patients. In HIV-negative patients,
several reports have suggested that rates of sus-
tained response can be markedly improved with
the addition of ribavirin to IFN-a therapy. Riba-
virin is a guanosine analog with broad-spectrum
antiviral activity against many RNA and DNA
viruses. Although ribavirin does not inhibit
HCV replication when given alone, it may signiﬁ-
cantly reduce transaminase levels and can
improve liver histology. Large multicenter rando-
mized controlled trials in HIV-seronegative
patients have shown that a combination of inter-
feron and ribavirin results in sustained response
rates of 28–40% or at least two-fold higher than
those seen with interferon monotherapy [23]. Sus-
tained virologic response is strongly related to
HCV genotype, ranging from 17% to 29% in
patients with genotype 1, to 65–67% in those with
genotypes 2 or 3, with 6 or 12months of therapy,
respectively. In addition to viral genotype, sus-
tained virologic response depends on different
factors such as duration of therapy and viral load,
as well as the age and sex of patients.
As yet, there are few published articles on the
effect of IFN-a and ribavirin combination therapy
in HCV/HIV-co-infected patients, but preliminary
results seem very promising [24–27]. The majority
of patients included in these trials were young
men, former drug users or hemophiliacs receiving
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HAART, with high CD4 cell counts and low HIV
viral loads. Landau et al. [26] achieved, with com-
bination therapy, clearing of serum HCV RNA at
the end of 6 months of treatment in 50% of 20
patients. In a second study, end-of-treatment
response was achieved in 73% of 12 patients trea-
ted for 6 months [27]. However, a sustained vir-
ologic response was found by Zylberberg et al. [24]
in only 14% of 20 patients who were previous non-
responders to interferon therapy. This very low
sustained rate of response to interferon in non-
responders parallels those obtained in the general
population [28].
Very limited data are currently available on the
safety and tolerance of the IFN-a and ribavirin
combination therapy in HIV infection. The most
serious side-effect of ribavirin is hemolytic anemia.
The incidence of anemia seems to be much higher
in HIV-infected patients than among HIV-non-
infected patients [24]. Treatment discontinuation
is usually the result of anemia and neutropenia,
particularly in patients receiving zidovudine at the
same time as ribavirin. Moreover, a recent report
suggests that ribavirin, a nucleoside analog, can
increase the risk of mitochondrial toxicity in HIV-
infected patients already treated with nucleoside
analogs, leading to clinical deterioration in some
cases [29]. On the other hand, there has been some
concern about administering ribavirin to HIV-
infected individuals because of potential inhibi-
tion of the phosphorylation of zidovudine and
stavudine [30]. In a recent study, however, there
was no signiﬁcant variation in HIV viral load after
6months of treatmentwith ribavirin inHCV/HIV-
co-infected patients receiving zidovudine and sta-
vudine [24]. The usual dose of rivabirin in immu-
nocompetent individuals is 1000–1200mg/day
plus 3MU of interferon, three times weekly,
for 6–12months. However, severe depletions of
CD4 cells have been observed with doses of
1200–1600mg [31]. Thus, a lower dose of riba-
virin would probably be better in HIV/HCV-co-
infected patients (i.e. 800mg/day); several clin-
ical trials are currently in progress to conﬁrm
this.
Recent reports have suggested that HAART
may result in severe liver disease as a result of
an improvement in T-cell-mediated immunity
upon effective immune restoration, or through
direct hepatotoxicity of protease inhibitors in
HIV-seropositive patients co-infected with HCV
[32]. Hepatotoxic manifestations are seen in nearly
14% of HIV/HCV-co-infected patients after start-
ing HAART. Such results emphasize the conve-
nience of treating HIV-infected patients suffering
from chronic hepatitis C with IFN-a and ribavirin
before the introduction of antiretroviral therapy
(i.e. with CD4þ T-lymphocyte count >350/mm3).
Moreover, early treatment before the need for
anti-HIV therapy, would overcome the potential
problem of drug interactions during the treatment
of HIV-positive patients.
Despite efforts to achieve HCV eradication
with the incorporation of new drugs and new
therapeutic strategies, no more than half of the
patients with chronic hepatitis C infection respond
to standard treatment with interferon plus riba-
virin. Thus, new pharmacologic options are need-
ed. Investigations on viral kinetics have shown
that daily dosing of interferon is superior to
administration every other day. Therefore, pegy-
lated interferons which are given once a week
were designed and have been shown to result in
stable plasma trough levels. Preliminary results in
HIV-seronegative patients look very promising
[33]. Unfortunately, there are no published reports
of experience with this drug in HIV-infected
individuals.
Orthotopic liver transplantation is the only
effective treatment for immunocompetent patients
with HCV advanced liver disease. In the 1980s,
before the availability of HIV screening tests, sev-
eral transplant recipients acquired HIV from con-
taminated organs or blood products [34,35]. At this
time, it was observed that the survival rate of HIV-
positive transplant recipients was inferior to that
of HIV-negative recipients. Many of these patients
died prematurely as a consequence of opportunis-
tic infection and rapid progression to AIDS.
With the development of effective HAART,
increasing numbers of patients with stable HIV
infection are progressing to end-stage liver failure.
Nevertheless, attitudes to the transplantation of
HIV-infected patients have been slow to adjust,
and many transplant centers still consider HIV
infection to be a contraindication to organ
transplantation.
Currently, there is little published data concern-
ing liver transplantation for stable HIV-infected
patients with a low viral load. Recent case reports
demonstrate that a good short-term outcome can
be expected and long-term survival with a good
quality of life is possible [36–38]. Ideally, HIV-
infected liver transplant candidates should not
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be addicted to drugs should have undetectable
HIV viral load, should have a CD4 count above
200/mm3, should have no opportunistic infec-
tions, and should be able to fulﬁll all the socio-
logical and psychological requirements for a liver
transplant within the general population [39].
Unfortunately, HAART therapy has side-effects:
the interaction with other drugs is such that con-
comitant use with immunosuppressive drugs
after transplantation is a challenge. In view of
the complexities and uncertainties of liver trans-
plantation in HIV-infected patients, it seems pru-
dent for such procedures to be limited to a small
number of centers which can develop the appro-
priate experience.
In summary as the life-expectancy of HIV-
infected patients increases, it is increasingly more
important to consider the deleterious impact of
HIV infection in their treatment. As in immuno-
competent patients, HCV therapy in HIV-infected
individuals is associated with modest clinical and
virologic success. Future studies have to focus on
the impact of new therapies, including liver trans-
plantation, in the natural history of HCV infection
in HIV-infected individuals.
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